Home › Funds › Vivo Capital, LLC › MNPR

Vivo Capital, LLC position in MNPR

Monopar Therapeutics Inc · Health Care

Vivo Capital, LLC reported holding 90,500 shares of MNPR (Monopar Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$7.2M, representing 0.82% of its reported portfolio and ranking #32 among its reported holdings. Vivo Capital, LLC has disclosed MNPR holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)90.50K sh
Reported value held$7.21M
Portfolio Weight0.82%
First reportedQ3 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Vivo Capital, LLC's MNPR position evolved

Vivo Capital, LLC first disclosed a stake in MNPR in Q3 2025 at 90,500 shares (US$7.4M). The position peaked in Q2 2026 at 90,500 shares, worth US$8.4M. Across 5 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 90,500 shares valued at US$7.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 90.50K $7.39M New
Q4 2025 90.50K $5.91M Hold
Q1 2026 90.50K $4.96M Hold
Q2 2026 90.50K $8.38M Hold
Q3 2026 90.50K $7.21M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MNPR and 13F data

MNPR (Monopar Therapeutics Inc) is a Health Care company. 76 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$61.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Saturn V Capital Management LP (US$28.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MNPR

All MNPR fund holders →

FAQ

How long has Vivo Capital, LLC held MNPR?

Vivo Capital, LLC has disclosed MNPR holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Vivo Capital, LLC's current position in MNPR?

As of Q3 2026, Vivo Capital, LLC holds 90.50K shares of MNPR (Monopar Therapeutics Inc), valued at $7.21M, representing 0.82% of its reported portfolio and ranking #32.

Has Vivo Capital, LLC been buying or selling MNPR?

In the latest 13F filing (Q3 2026), Vivo Capital, LLC held unchanged its position in MNPR. The position peaked in Q2 2026 at 90.50K shares.

Which other funds hold MNPR?

Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Saturn V Capital Management LP, among 76 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.